antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E antibody-vector-A antibody-vector-B antibody-vector-C antibody-vector-D antibody-vector-E

Antibody-based therapies to fight cancer

AgilVax Discovers and Develops Targeted Antibody-Based Therapeutics for Metastatic Cancer

AgilVax is developing an antibody-drug conjugate, xCT-ADC, that targets xCT (SLC7A11), an amino acid transporter, which exports glutamate in exchange for cystine, a precursor for the synthesis of the antioxidant glutathione, which normally protects cells from oxidative and chemical insults.

Cancer cells utilize xCT as means to facilitate growth and survival. xCT is overexpressed in numerous cancer types including but not limited to colorectal, breast, non-small cell lung, liver, and pancreatic cancers. xCT expression in tumor cells has been linked to resistance to anti-cancer drugs, induction of tumor growth, cancer cell proliferation, survival, cell invasion, tumor metastasis, and reduced patient survival. This makes xCT a promising pharmacological target for multiple metastatic cancers. AgilVax is developing the optimized antibody-based strategy to target xCT and provide cancer patients with a meaningful therapeutic option.

In addition to xCT-ADC AgilVax is leveraging its expertise to build a portfolio of antibody based therapeutic candidates that target metastatic cancer.

Download Factsheet

Latest News

View All News

Investors